About

EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower RespiratoryTract RSV Symptoms and Viral Load After Human Viral Challenge